Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2
- 1 January 1994
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 30 (8), 1078-1083
- https://doi.org/10.1016/0959-8049(94)90460-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinomaEuropean Journal Of Cancer, 1993
- Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinomaEuropean Journal Of Cancer, 1992
- Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell CancerArchives of Surgery, 1991
- High gradient magnetic cell separation with MACSCytometry, 1990
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Lymphokine-activated killer cells. Analysis of progenitors and effectors.The Journal of Experimental Medicine, 1986
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984